Shuang Hor is a pioneer in the R & D of Lingzhi products. The first generation Yung Kien Ganoderma has helped countless people regain optimal health and even saved many lives after its introduction into the market. Today, having successfully taken the market by storm, the second generation Yung Kien Ganoderma not only marks a new milestone in the field of Lingzhi technological research and development, but also adds another feather to the cap of Shuang Hor’s competitive edge in Lingzhi R & D.
In conjunction with the launch of this ground-breaking product, Shuang Hor specifically invited the man behind the research and development programs of Yung Kien Ganoderma 2, who is none other than Dr. Chen Deng Hai of Shuang Hor Group’s Bio-Technology R & D Institute (BTRI), to conduct 6 rounds of road-show seminar in Malaysia and Singapore, serving to impart fellow distributors and consumers with useful knowledge pertaining to the special attributes and efficacies of this latest product. During the seminar, Taiwan Gold Diamond also joined Dr. Chen Deng Hai in the Q & A sessions, allowing the participants to acquire a more in-depth understanding of the product and have their confidence in its long-term consumption significantly boosted.
Excerpt of Dr. Chen Deng Hai’s presentation:
“The motive behind the R & D of Yung Kien Ganoderma 2 is principally to cater to our customers who have specific needs, with many of them having to consume large doses of the first generation Yung Kien Ganoderma in order to see its health improvement results. For those people who have difficulty in swallowing, the need to gulp down 10 to 20 capsules a day can indeed prove to be a daunting experience. That is exactly the reason why many patients discontinued with its consumption, leading to the loss of opportunity in improving health or even saving lives. It was under this background that BTRI began its R & D drive 5 years ago with the objective of substantially reducing the consumption amounts and yet maintaining the efficacy of our Lingzhi health food. “For patients of critical diseases, triterpenoids as an effective constituent of Lingzhi offer remarkable curative benefits. As such, we were inspired to work on bringing about a compositional realignment of this effective constituent in the product. However, this was easier said than done. We had not been able to achieve this through the traditional methods of extraction and concentration, but had to rely on the state-of-the-art purification techniques. In fact, triterpenoids as a special group of compounds are found naturally occurring only in Lingzhi. They exhibit amazing attributes in modulating the immune functions, protecting the liver, retarding ageing, relieving the condition of allergic physical constitution, subduing cancer growth, reducing blood lipids, bringing down blood pressure, inhibiting HIV, reducing inflammation, preventing prostate enlargement, enhancing learning ability, and improving memory. Our collaboration with Taiwan National Research Institute of Chinese Medicine has led to the discovery that triterpenoids also possess anti-fibrotic effects. Besides, triterpenoids have been shown to be helpful in reducing inflammatory symptoms in the respiratory tract and liver as well. “During the 1970’s and 1980’s, the bio-tech fraternity tended to be in favour of research works involving polysaccharides, which could be more readily isolated and were much richer in compositional percentage. In contrast, research works in triterpenoids were not popular, as this constituent of Lingzhi was simply too difficult to be isolated and was available only in minute traces. It was not until a later stage, and thanks to successful large scale artificial cultivation of Lingzhi and the discovery of triterpenoids, notably ganoderic acids, that researchers began a serious study in this special group of effective constituent in Lingzhi. The end of 2005 saw an increasingly bigger number of research papers pertaining to new findings on the anti-cancer attributes of triterpenoids, which led to the confirmation that the content of triterpenoids, to be followed by polysaccharides (peptides) and adenosines in that order, is the primary factor differentiating a superior Lingzhi spawn from the less efficacious ones. Among the various effective constituents of Lingzhi, as polysaccharides merely play the indirect role of beefing up our immunity to ward off viral attacks, their consumption in large doses is not necessary. On the other hand, since triterpenoids are directly involved in waging wars against the intruding viruses or cancel cells, the higher their consumption dosage, the better it would be the health improvement benefits for patients suffering from critical diseases.
“In Western medicines, many of the notable natural drugs are formulated through the process of purification. As most of the medicinal formulations today more often than not produce side effects in the human body, it has become the keen pursuit and ultimate objective of Western medicines to develop drugs that do not entail such unfavourable effects. This is however something that we have already achieved, as consuming Lingzhi in large amounts is known to bring no side effect. On top of this, research findings also point to the fact that Lingzhi triterpenoids promise the greatest potential in being developed into highly effective crude drugs. As a business entity equipped with the most resourceful corporate strength in the world pertaining to the R & D domain of Lingzhi triterpenoids, Shuang Hor Group has invested almost a king’s ransom in procuring the purification instruments and facilities essentially needed to produce high purity health-care products for the benefits of the masses. Through the synergy of hardware and software complementation, we arrived at the conclusion that large scale production of Lingzhi triterpenoids was feasible. In the year 2008, we succeeded in purifying triterpenoids, with the content of up to 9 types of ganoderic acids purified to a level of exceeding 50%. In the following year, the pilot project became a success along with technological transfer to Yung Kien Factory for mass production. We also went on to apply for a patent right for the production process, with the objective of making Shuang Hor Group the only legitimate business entity to produce and market Yung Kien Ganoderma 2. This patent right application is entitled “Ganoderma Extract with High Amounts of Ganoderic (Lucideric) Acids and Method for Producing the Same”. “As far as the raw material or ingredient is concerned, Yung Kien Ganoderma 2 is basically the same as its predecessor Yung Kien Ganoderma. But the two differ in one aspect, namely the fruiting bodies for the former have to be cultivated in a computerized high-tech greenhouse. These triterpenoids are subject to stringent screening to ensure that the composition gives a rich content of ganoderic acids before they qualify as a raw ingredient for production. The processing involves the incorporation of purified ganoderic acids into the first generation of Yung Kien Ganoderma. The mixture is then subject to a freeze-drying process called ‘lyophilisation’ before filling into capsules. Upon purification, its content of 9 types of ganoderic acids (A, B, C, etc) has increased to 12% and above, which is 6 times of Yung Kien Ganoderma. This means that a capsule of Yung Kien Ganoderma 2 is equivalent to 6 capsules of Yung Kien Ganoderma in potency. As far as patients of critical diseases are concerned, this translates into doing away with the need to swallow large doses, as in the case of Yung Kien Ganoderma, and yet gives the same efficacy. While retaining the effective constituents and the attribute of safe consumption, Yung Kien Ganoderma 2 constitutes an upgraded product featuring a rich content of triterpenoids, thus benefiting from the marriage between agricultural bio-technology and bio-chemistry purification techniques. “Yung Kien Ganoderma 2 is exclusively intended for people who are unable to consume large doses (more than 20 capsules a day) and those in need of large amounts of ganoderic acids. It is also extremely beneficial for patients suffering from autoimmune diseases, such as asthma, allergies, lupus erythematosus, rheumatoid arthritis, myasthenia gravis, psoriasis, etc. This second generation product is remarkably helpful as well for people who suffer from viral hepatitis, liver fibrosis, cancer, AIDS, and so on. In other words, Yung Kien Ganoderma 2 is only recommended for patients who have specific needs. As for ordinary consumers who merely look for everyday health maintenance, the consumption of Yung Kien Ganoderma is already good enough. “In spite of the fact that Shuang Hor Group is destined to own patent rights for its core technologies and has emerged as a leading force to be reckoned with in the marketing of Lingzhi products, our quest in Lingzhi R & D will remain relentless. And we will continue with our devoted endeavour to become ever more professional in the progress made so far. Our next goal is to introduce Lingzhi formulations with targeted efficacies, with which we can develop into different food supplements or adjunct foods to help many more people regain health and assist even more people to extend their life expectancy.”
Source - Shuang Hor Magazine JULY 2011